openPR Logo
Press release

Argenta and BioFocus announce two-year extension of drug discovery collaboration with Genentech

08-31-2011 07:42 AM CET | Science & Education

Press release from: BioFocus

/ PR Agency: Alto Marketing
Galapagos NV (Euronext: GLPG) announced today that its service division Argenta has extended its integrated contract drug discovery agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). Total potential value of the contract extension is up to £21.5 million (€23.4 million).

This is the third such extension since the agreement was announced in December 2005. The agreement covers a number of drug discovery programs that utilize Argenta's expertise in computer-aided drug design (CADD), medicinal chemistry, in vitro biology and screening to discover new chemical entities acting against undisclosed drug targets defined by Genentech.

The extended agreement also allows Genentech to continue placing projects directly into Galapagos’ other service division, BioFocus, who will provide Genentech with integrated medicinal chemistry, in vitro biology and ADME services. BioFocus has been working with Genentech since an amendment to the Argenta agreement was signed in September 2010.

“We are proud that Genentech again has selected Argenta for this major drug discovery collaboration,” said Dr Chris Newton, SVP Services of Galapagos. “The possibility for Genentech to continue placing projects directly with BioFocus also speaks to the complementary expertise and technological capabilities that Argenta and BioFocus possess.”

About Argenta

Argenta’s contract research, which includes expertise in medicinal chemistry, computer-aided drug discovery, in vitro biology, analytics, in vivo pharmacokinetics, pharmacology and world-leading respiratory models, has a strong reputation for scientific excellence. Argenta is a service division of Galapagos NV (Euronext: GLPG) and employs over 140 people in the UK with its main operations in Harlow. More info at:

About BioFocus

BioFocus delivers drug discovery solutions through a comprehensive platform run by dedicated teams with a track record in gene-to-clinical candidate discovery. BioFocus’ offering includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry and ADME/PK services, supported by unique chemogenomic and informatics tools. As a service division of Galapagos, BioFocus has over 210 employees with research facilities in three countries. For more information visit

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing one of the largest pipelines in biotech, with six programs in development and over 50 discovery programs. Through risk/reward-sharing alliances with GlaxoSmithKline, Lilly, Janssen Pharmaceutica, Roche and Servier, Galapagos is eligible to receive up to €2.5 billion in downstream milestones, plus royalties. The Galapagos Group has about 800

Alto Marketing
Office 3 | Universal Marina | Crableck Lane | Sarisbury Green | Southampton | SO31 7AL | UK

Media enquiries
Alto Marketing Limited:
Paul Avery
Tel: +44 1489 557 672

Company enquiries
Dr Chris Newton, SVP Galapagos Services
Tel: +44 1799 533 535

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Argenta and BioFocus announce two-year extension of drug discovery collaboration with Genentech here

News-ID: 189792 • Views: 1553

More Releases from BioFocus

BioFocus and InterMed Discovery announce Marketing Collaboration
BioFocus, an integrated drug discovery service partner, and InterMed Discovery GmbH (IMD), a natural product lead-discovery company, today announced a marketing collaboration to offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries. No financial details were disclosed. Under the terms of the collaboration, IMD will make its natural product screening libraries available and provide follow-on services to BioFocus. BioFocus will then incorporate these as part of
BioFocus enters collaboration with Michael J. Fox Foundation
BioFocus announced today that it has signed a collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease. Under the agreement, BioFocus will perform fragment-based screening, assay development and hit-finding programs, to identify compounds that have the basis for a novel Parkinson’s disease diagnostic test. “We are delighted to have the opportunity to support The Michael J.
BioFocus extends collaboration with Usher III Initiative
BioFocus announced today that it has expanded a collaboration with the Usher III Initiative, Inc., a non-profit organization focused on developing treatments for Usher syndrome type III, a rare genetic disorder that causes the loss of hearing and vision. BioFocus and the Usher III Initiative began their collaboration in July 2010 with BioFocus performing an integrated drug discovery program encompassing medicinal chemistry, ADME and biological sciences, aiming at a
Astellas Pharma and BioFocus sign target discovery agreement
BioFocus announced today that it has signed a collaboration agreement with Astellas Pharma Inc. focused on discovering novel targets in the field of CNS disorders. Under the agreement, BioFocus will utilize its SilenceSelect® target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration. “We are delighted to support Astellas Pharma

All 5 Releases

More Releases for Galapagos

Galapagos Islands 18+ Population 100% Vaccinated
**Metropolitan Touring Joins Group of Travel Operators to Support the Vaccination Campaign in the Galapagos Islands – and Sees Encouraging Results** (Quito, Ecuador) – COVID-19 vaccinations are key to reactivating tourism around the world – especially in remote destinations like the Galapagos Islands. With travel to the archipelago that inspired Charles Darwin in the balance, Metropolitan Touring joins eight other travel companies to support the government of Ecuador’s COVID-19 vaccination
Investigation for Investors in shares of Galapagos NV (NASDAQ: GLPG) announced
An investigation was announced concerning potential securities laws violations by Galapagos NV in connection with certain financial statements. Investors who purchased shares of Galapagos NV (NASDAQ: GLPG), have certain options and should contact the Shareholders Foundation at or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Galapagos NV regarding its business, its prospects and its operations were materially false and
Latin Trails announces a special end of the summer promotion available for all its clients on the company’s first class top of the line yacht, the M/Y Galapagos Odyssey. The special offer consists of including the INGALA migration card, the Galapagos Islands National Park entrance fee and even the roundtrip flight Ecuador mainland/Galapagos! This promotion will be available for all departures in the following dates: • August 16 to September 18,
Huge success on M/Y Galapagos Grand Odyssey’s opening tours
Latin Trails is pleased to announce that the first tours of the Galapagos Islands on board their latest luxury boat, the M/Y Galapagos Grand Odyssey, have been a great success! The latest addition to their collection has only been sailing since February 1, 2011 running the first tour on the 15th of that same month, but is already delighting passengers lucky enough to enjoy its one of a kind
Insider's Galapagos Joins the Network of Sustainable Travel Operators
With the launch of a new online booking site the Galapagos Islands has become the first destination in Ecuador. Quito, Ecuador, March 09, 2011 -- The most recent Ecuadorian company to join the network, Yacu Amu Experiences, is eager to spread the word about these constantly evolving islands through it's Insider's Galapagos brand. “We are very excited to be partnering with to connect small hotels and tour operators
Red Mangrove Galapagos and Ecuador Lodges Opens Scuba Dive Lodges on Santa Cruz …
Two New Lodges for Divers to Augment Three Sister Island Eco-Lodges - Will Serve Red Mangrove’s New Dive Academy Scheduled to Open Spring 2011 QUITO, ECUADOR, Dec. 22, 2010 – Red Mangrove Galapagos and Ecuador Lodges announces the Dec. 1 openings of the 9-room Santa Cruz Divers Lodge in Puerto Ayora on Santa Cruz Island and the 5-room Isabela Divers Lodge in Puerto Villamil on Isabela Island in the Galapagos. This